VENLO, the Netherlands, February 1, 2017 /PRNewswire/ --
- Ongoing momentum in fourth quarter supports strong 2016 performance:
● Q4 2016:
-Net sales $366.5 million (+5% actual, +8% CER vs. +8% CER guidance)
-EPS $0.04; adjusted EPS $0.15 ($0.16 CER vs. $0.15-0.16 CER guidance),
adjusted EPS excl. charge $0.39 ($0.41 CER vs. $0.38 CER guidance)
● Full-year 2016:
-Net sales $1.34 billion (+4% actual, +6% CER vs. +6-7% CER guidance)
-EPS $0.34; adjusted EPS $0.87 ($0.90 CER vs. $0.87-0.88 CER guidance),
adjusted EPS excl. charge $1.11 ($1.14 CER vs $1.10-1.11 CER guidance)
-Free cash flow rises 22% to $267 million
- QIAGEN reaffirms full-year 2017 outlook for 6-7% CER sales growth and adjusted EPS target before restructuring costs of $1.25-1.27 CER
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2016, delivering on goals for improvements in net sales and adjusted earnings.
"QIAGEN's performance during 2016 shows our transformation is building momentum thanks to the power of our Sample to Insight portfolio and we are moving ahead on a new growth trajectory," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "We have strengthened our position as a global leader in molecular testing, and we expect to make significant progress in 2017."
Click here for full press release
Vice President Corporate Communications and Investor Relations
Dr. Sarah Fakih
Associate Director Investor Relations
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
Download the QIAGEN Investor Relations App
SOURCE QIAGEN N.V.